ACE shifts the angiotensin pathway toward angiotensin II by cleaving angiotensin I. Angiotensin II increases vascular resistance through vasoconstriction, so changes in ACE activity can alter circulatory pressure. This provides a mechanistic link between peptide processing and cardiovascular regulation, rather than treating blood pressure as an isolated vascular response.
Bradykinin acts as a vasodilator, so its breakdown removes a signal that promotes vessel relaxation. ACE therefore affects vascular tone through two complementary peptide pathways: it generates the vasoconstrictor angiotensin II and reduces the availability of bradykinin. Considering both pathways helps explain the broader cardiovascular consequences of ACE activity.
Angiotensin II promotes aldosterone release, linking ACE activity to sodium and water retention. These changes affect fluid balance and contribute to blood-pressure regulation through renal and circulatory physiology. Studying this connection shows how peptide signaling can coordinate vascular resistance with the body's handling of salt and water.
As a membrane-bound peptidase, ACE is positioned at a cellular interface where it can process signaling peptides associated with vascular and circulatory regulation. This organization places peptide cleavage within a regulated biological setting instead of treating the reactions as independent events. Its localization is therefore relevant when interpreting how ACE activity influences cardiovascular function.
ACE provides a model for examining how hormone-like peptide signals produce coordinated physiological effects. Researchers can relate its activity to angiotensin II formation, bradykinin breakdown, vascular resistance, aldosterone release, and fluid balance. This makes the system useful for connecting molecular processing with renal and cardiovascular outcomes in biology.
ACE inhibitor drugs target the enzyme's activity to modify the signaling processes that influence vascular resistance, aldosterone release, and fluid balance. Their clinical use includes hypertension, heart failure, and related cardiovascular conditions. In research, these drugs also help reveal how changing peptide-processing activity affects integrated cardiovascular and renal physiology.